Cancer/Oncology Drugs Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 192.39 Bn

Forecast Year, 2035

USD 554.69 Bn

CAGR, 2026 - 2035

11.17%

Report Coverage

Global

What is the Cancer/Oncology Drugs Market Size?

The global cancer/oncology drugs market size is calculated at USD 192.39 billion in 2025 and is predicted to increase from USD 214.70 billion in 2026 to approximately USD 554.69 billion by 2035, expanding at a CAGR of 11.17% from 2026 to 2035.

Cancer/Oncology Drugs Market Key Takeaways

• North America led the global market with the highest market share of 45% in 2025.
• By class type, the targeted therapy segment has held the largest market share of 50% in 2025.
• By indication, the lung cancer segment captured the biggest revenue share in 2025.

How is AI contributing to the Cancer/Oncology Drugs Market?

AI plays a major role in the development of oncology drugs by revealing the potential of drugs, forecasting how different compounds will act, and allowing the repurposing of already existing molecules. AI makes a more accurate diagnosis by spotting fine tumor patterns in imaging, which in turn enhances the accuracy of the diagnosis. Moreover, AI significantly reduces the entire development time and helps to advance cancer treatment based on data quickly.

Cancer/Oncology Drugs Market Growth Factors

The global cancer drugs market is primarily driven by the increasing prevalence of various types of cancer among the global population. As per the GLOBOCAN, a report published by the International Agency for Research on Cancer, around 19.3 million new cancer cases and 10 million cancer deaths were reported across the globe, in 2020. The new cancer cases are expected to rise by 47% from 2020 to 2040, globally. Therefore, it is estimated that around 28.4 million new cancer cases will be recorded in 2040 across the globe. The most prominent types of cancer include lungs cancer, breast cancer , prostate cancer, and colorectal cancer. Moreover, the rapid developments in the biopharmaceutical market has resulted in the development of various new and innovative drugs that can efficiently target the cancer cells without harming the normal cells. The increased awareness among the population regarding the availability of various advance therapeutics to treat cancer is significantly driving the growth of the global cancer drugs market. The rising investments by various pharmaceutical companies in the research and development of various new cancer drugs is expected to provide new growth avenues in the forthcoming future.

Cancer/Oncology Drugs Market Outlook

[[market_outlook]]

Market Scope

Cancer/Oncology Drugs Market Segment Insights

[[segment_insights]]

Cancer/Oncology Drugs Market Regional Insights

[[regional_insights]]

Cancer/Oncology Drugs Market Value Chain Analysis

[[value_chain]]

Key Companies & Market Share Insights

The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improved products. Moreover, they are also focusing on maintaining competitive pricing.

In April 2020, F.Hoffmann-La Roche launched Atezolizumab, an immunotherapy medicine in India, for the treatment of breast cancer.

The various developmental strategies like new product launches, acquisitions, and mergers fosters market growth and offers lucrative growth opportunities to the market players.

Cancer/Oncology Drugs Market Companies

[[market_company]]

Other Major Key Players

• GlaxoSmithKline
• ARIAD Pharmaceuticals, Inc.
• Eli Lilly and Company
• Novartis
• Hoffmann-La Roche Ltd.
• AstraZeneca
• BoehringerIngelheim GmbH
• Pfizer
• Teva Pharmaceuticals Industries

Segments Covered in the Report

[[segment_covered]]